Related Experiment Video
Updated: Oct 17, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
Therapy with thalidomide in refractory multiple myeloma patients - the revival of an old drug
A Kneller1, P Raanani, I Hardan
1The Institute of Haematology, The Chaim Sheba Medical Centre, Tel-Hashomer, and Sackler School of Medicine, Tel-Aviv University, Israel.
Abstract:
We have treated 17 refractory or relapsed multiple myeloma patients resistant to chemotherapy with thalidomide at a dose of 200-800 mg/day. Eleven patients responded, five of whom had a very good partial response (> 75% decline in M protein) and another five exhibited a partial response (> 50% decline in M protein). Except for one patient, treatment was well tolerated with only mild side-effects. Thalidomide should be included in the therapeutic options for refractory myeloma.
Related Concept Videos
Treatment Resistant Cancers
Drug Therapy
Antianxiety Medications
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Therapeutic Drug Monitoring: Overview and Classification
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...